查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2030 年神经遗传学测试市场预测：按类型、最终用户和地区分類的全球分析
市场调查报告书
商品编码
1383476

2030 年神经遗传学测试市场预测：按类型、最终用户和地区分類的全球分析

Neurogenetic Testing Market Forecasts to 2030 - Global Analysis By Type (Microarray Analysis, Whole-Exome Sequencing, Multiplex Ligation Dependent Probe Amplification, Polymerase Chain Reaction Tests and Other Types), By End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC预测，2023年全球神经遗传学检测市场规模将达6.167亿美元，预测期内年复合成长率为12.1%，预计到2030年将达到13.721亿美元。

神经遗传学测试涉及检查个体的基因组成，以识别与神经系统疾病相关的特定遗传变异。其应用包括诊断神经系统疾病、评估风险因素和指导个体化治疗计划，从而实现更有针对性和更有效的医疗保健干预措施。

根据世界卫生组织报告，欧洲地区神经系统疾病负担占全球的11.2%，其次是西太平洋地区，占10%。

神经系统疾病盛行率上升

人们对阿兹海默症、帕金森氏症和各种神经发育障碍等疾病的认识和了解不断增加，推动了对准确和早期基因检测的需求不断增长。神经遗传学检测的进步为了解这些疾病的遗传倾向和危险因素提供了一个窗口，有助于早期诊断和有针对性的治疗计划。随着这些疾病受到更多关注和医学认识的进步，对有效的神经遗传学检测的需求将使我们能够定制干预措施，实现更好的管理，并应对这些挑战，包括神经系统疾病的发病和进展。或延迟

与测试相关的成本高且可近性有限

基因检测方法的复杂性，加上对专门设备和专业知识的需求，导致检测急剧上升，使许多人无法承担这些服务。此外，先进的神经遗传学检测的机会有限，特别是在贫困和偏远地区，限制了这些重要诊断工具的可用性。因此，在获得尖端医疗保健解决方案方面的差距仍然存在，使许多人无法从神经系统疾病的早期诊断、个体化治疗和风险评估中受益。

研发进度

基因检测技术的不断进步，加上对神经系统疾病遗传基础的深入了解，正在推动更复杂、更准确和更全面的检测方法的发展。这项进步不仅扩大了可进行基因检测的疾病范围，也提高了诊断的准确性和可靠性。此外，它还促进了新的遗传标记和潜在治疗标靶的发现，促进了神经病学个人化医疗的发展。

基因检测方法的复杂性

基因检测技术通常涉及难以实施和理解的复杂过程，例如定序、微阵列分析和基因突变的解释。对高度专业化的设备、训练有素的专业人员和广泛的生物资讯分析的需求可能会导致高昂的营运成本和有限的高级测试机会。此外，这些测试的复杂性可能会导致错误、资料误解或误诊，从而影响其可靠性和准确性。此外，基因检测的复杂性可能会阻碍医疗保健提供者和患者接受这些诊断工具，特别是在技术基础设施和医疗保健专业知识有限的地区。

COVID-19 的影响：

COVID-19大流行对市场产生了重大影响，带来了挑战和机会。儘管供应链和临床业务最初的中断影响了检测的机会，但了解病毒对神经系统影响的紧迫性加速了神经遗传学的研究和开发。远端医疗和远距测试已成为人们关注的焦点，使患者的访问和诊断变得更加容易。这段时期，神经系统疾病基因检测的重要性被强调，刺激了检测技术的投资和创新。儘管最初遇到了挫折，但这场大流行促使人们取得进展，并让人们更加认识到神经遗传学测试在医疗保健中所发挥的重要作用，并有可能重塑市场的未来格局。

聚合酶炼式反应（PCR）检测领域预计在预测期内规模最大

聚合酶链反应（PCR）检测占有很大的市场份额。 PCR 扩增 DNA 片段的能力可以帮助检测与亨廷顿氏症和帕金森氏症等疾病相关的突变。其高特异性和灵敏度能够准确分析遗传标记，这对于早期诊断和疾病监测至关重要。 PCR 的作用延伸到神经病学、药物开发和个人化医疗的研究，促进对疾病遗传基础的理解取得进展。作为基本工具，PCR 检测不断革新神经遗传学检测，并培养塑造研究和临床方法的见解。

预计医院领域在预测期内的年复合成长率最高。

在预测期内，医院的年复合成长率最高。医院提供先进的检测设施，实现全面的基因筛检，并协助识别神经遗传疾病。这些机构正在将检测整合到诊断途径中，促进疾病的早期发现和个体化治疗策略。该医院还透过汇集遗传学家、神经学家和其他专家来提供全面的护理，为正在进行的研究做出贡献，并引入尖端的测试方法，从而推进神经遗传学测试。它还作为跨学科合作的中心，大大塑造了景观。

占比最大的地区：

北美占据重要地位，预计在预测期内将占据最大份额。该地区是大型生物技术和製药公司的所在地，促进创新并推动尖端检测方法的发展。在神经系统疾病盛行率较高且医疗保健系统积极的北美，神经遗传学检测已广泛应用于临床和研究领域。该区域市场的特点是强有力的法律规范、学术界和工业界之间的战略合作伙伴关係以及对个人化医疗的日益关注，使北美在神经遗传学检测领域处于领先地位的地位正在巩固。

复合年复合成长率最高的地区：

亚太地区的年复合成长率最高。该地区人口众多且多样化，神经系统疾病负担沉重，增加了对先进诊断解决方案的需求。此外，新兴经济体的存在和政府的支持措施正在促进亚太地区工业界和研究机构之间的合作，扩大检测范围，并不断发展客製化的神经系统疾病诊断和管理方法。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球神经遗传学测试市场：按类型

  • 微阵列分析
  • 全外EXOME定序（WES）
  • 多重连接依赖性探针扩增 (MLPA)
  • 聚合酶连锁反应（PCR）测试
  • 其他类型

第6章全球神经遗传学测试市场：依最终用户分类

  • 医院
  • 专科诊所
  • 研究机构
  • 诊断实验室
  • 其他最终用户

第7章全球神经遗传学测试市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第8章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第9章公司简介

  • Invitae Corporation
  • Ambry Genetics
  • PerkinElmer
  • GeneDx
  • Centogene
  • Blueprint Genetics
  • Genomic Health（Exact Sciences）
  • Fulgent Genetics
  • QIAGEN
  • Baylor Genetics
Product Code: SMRC24324

According to Stratistics MRC, the Global Neurogenetic Testing Market is accounted for $616.7 million in 2023 and is expected to reach $1372.1 million by 2030 growing at a CAGR of 12.1% during the forecast period. Neurogenetic testing involves examining an individual's genetic makeup to identify specific genetic variations associated with neurological conditions. Its uses include diagnosing neurological disorders, assessing risk factors and guiding personalized treatment plans, leading to more targeted and effective healthcare interventions.

According to a WHO report, the European region contributes 11.2% of global burden of neurological disorder followed by Western Pacific region with 10%.

Market Dynamics:

Driver:

Rising prevalence of neurological disorders

The growing recognition and understanding of conditions like Alzheimer's, Parkinson's, and various neurodevelopmental disorders prompt a heightened demand for accurate and early genetic testing. Advances in neurogenetic testing provide a window into the genetic predispositions and risk factors for these conditions, facilitating early diagnosis and precise treatment planning. As these disorders gain prominence and medical understanding evolves, the need for effective neurogenetic testing becomes pivotal in tailoring interventions, enabling better management, and potentially averting or delaying the onset and progression of these challenging neurological conditions.

Restraint:

High costs associated with testing and limited accessibility

The complex nature of genetic testing methods, coupled with the need for specialized equipment and expertise, contributes to elevated testing costs, making these services unaffordable for many individuals. Additionally, limited accessibility to advanced neurogenetic tests, especially in underprivileged or remote regions, restricts the reach of these crucial diagnostic tools. As a result, disparities in access to cutting-edge healthcare solutions persist, preventing many from benefiting from early diagnosis, personalized treatment, and risk assessment for neurological conditions.

Opportunity:

Increasing research and development

Ongoing advancements in genetic testing technologies, coupled with deeper insights into the genetic underpinnings of neurological disorders, drive the development of more sophisticated, accurate, and comprehensive testing methods. This progress not only expands the scope of disorders that can be genetically tested but also enhances the precision and reliability of diagnostics. Moreover, it fuels the discovery of novel genetic markers and potential therapeutic targets, fostering the evolution of personalized medicine in neurology.

Threat:

The complexity of genetic testing methods

Genetic testing techniques, which often involve intricate processes like sequencing, microarray analysis, and interpretation of genetic variations, can be challenging to implement and comprehend. The need for highly specialized equipment, skilled professionals, and extensive bioinformatics analysis can lead to high operational costs, limiting accessibility to advanced testing. Additionally, the intricate nature of these tests may result in errors, data misinterpretation, or misdiagnoses, impacting their reliability and precision. Furthermore, the complexity of genetic testing can deter healthcare providers and patients from embracing these diagnostic tools, particularly in regions with limited technological infrastructure or healthcare expertise.

COVID-19 Impact:

The COVID-19 pandemic significantly impacted the market, driving both challenges and opportunities. While initial disruptions in supply chains and clinical operations affected testing accessibility, the urgency to understand neurological implications of the virus accelerated research and development in neurogenetics. Telehealth and remote testing gained prominence, facilitating patient access and diagnosis. This period underscored the importance of genetic testing in neurological disorders, prompting increased investment and innovation in testing technologies. Despite initial setbacks, the pandemic spurred advancements and a broader recognition of the critical role neurogenetic testing plays in healthcare, potentially reshaping the market's future landscape.

The polymerase chain reaction (PCR) tests segment is expected to be the largest during the forecast period

The polymerase chain reaction (PCR) test has a significant share in the market. PCR's ability to amplify DNA segments aids in detecting mutations linked to disorders like Huntington's disease or Parkinson's. Its high specificity and sensitivity empower accurate analysis of genetic markers, crucial in early diagnosis and disease monitoring. PCR's role extends to research, drug development, and personalized medicine within neurology, driving advancements in understanding the genetic basis of conditions. As a foundational tool, PCR tests continue to revolutionize neurogenetic testing, fostering insights that shape both research and clinical approaches.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospital has the highest CAGR within the market over the forecast period. They offer access to sophisticated testing facilities, allowing comprehensive genetic screenings, aiding in the identification of neurogenetic disorders. These institutions integrate testing into their diagnostic pathways, facilitating early disease detection and personalized treatment strategies. Hospitals also serve as centers for multidisciplinary collaboration, bringing together geneticists, neurologists, and other specialists to provide holistic care, contributing to ongoing research, and implementing cutting-edge testing methodologies, thereby significantly shaping the landscape of neurogenetic testing.

Region with largest share:

North America holds a significant position and expected to hold a largest share over the forecast period. The region houses leading biotech and pharmaceutical companies, fostering innovation and driving the development of cutting-edge testing methodologies. With a high prevalence of neurological disorders and a proactive healthcare system, North America witnesses extensive adoption of neurogenetic testing across clinical and research domains. The market in this region is characterized by a strong regulatory framework, strategic collaborations between academic institutions and industry, and a growing emphasis on personalized medicine, solidifying North America's position at the forefront of neurogenetic testing advancements.

Region with highest CAGR:

The Asia Pacific region witnessed highest CAGR in the market. With a large and diverse population, this region encounters a notable burden of neurological disorders, propelling the need for advanced diagnostic solutions. Furthermore, the presence of emerging economies and supportive government initiatives fosters collaborations between industry and research institutions, paving the way for expanded accessibility to testing and fueling the evolution of tailored approaches for diagnosing and managing neurological conditions in the Asia Pacific.

Key players in the market

Some of the key players in Neurogenetic Testing Market include: Invitae Corporation, Ambry Genetics, PerkinElmer, GeneDx, Centogene, Blueprint Genetics, Genomic Health (Exact Sciences), Fulgent Genetics, QIAGEN and Baylor Genetics.

Key Developments:

In April 2023, Ambry Genetics and LifeStrands Genomics had collaborated to provide clinical genetic testing services in Singapore. Together, they have been chosen to support the Clinical Implementation Pilots (CIPs) for Phase II of Singapore's National Precision Medicine (NPM) programme through an open tender commissioned by Precision Health Research, Singapore (PRECISE) - the central entity implementing NPM.

In April 2023, Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that it will present new data highlighting the company's novel technology and approaches to early cancer detection at the American Association for Cancer Research® (AACR) Annual Meeting 2023 in Orlando, Florida.

In August 2022, PerkinElmer has signed an agreement with private equity firm New Mountain Capital for the sale of its Applied, Food and Enterprise Services businesses for $2.45bn in cash to allow the company to focus on its high-margin Life Science and Diagnostics businesses.

Types Covered:

  • Microarray Analysis
  • Whole-Exome Sequencing (WES)
  • Multiplex Ligation Dependent Probe Amplification (MLPA)
  • Polymerase Chain Reaction (PCR) Tests
  • Other Types

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Research Institutes
  • Diagnostics Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neurogenetic Testing Market, By Type

  • 5.1 Introduction
  • 5.2 Microarray Analysis
  • 5.3 Whole-Exome Sequencing (WES)
  • 5.4 Multiplex Ligation Dependent Probe Amplification (MLPA)
  • 5.5 Polymerase Chain Reaction (PCR) Tests
  • 5.6 Other Types

6 Global Neurogenetic Testing Market, By End User

  • 6.1 Introduction
  • 6.2 Hospitals
  • 6.3 Specialty Clinics
  • 6.4 Research Institutes
  • 6.5 Diagnostics Laboratories
  • 6.6 Other End Users

7 Global Neurogenetic Testing Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Invitae Corporation
  • 9.2 Ambry Genetics
  • 9.3 PerkinElmer
  • 9.4 GeneDx
  • 9.5 Centogene
  • 9.6 Blueprint Genetics
  • 9.7 Genomic Health (Exact Sciences)
  • 9.8 Fulgent Genetics
  • 9.9 QIAGEN
  • 9.10 Baylor Genetics

List of Tables

  • Table 1 Global Neurogenetic Testing Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
  • Table 4 Global Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
  • Table 5 Global Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
  • Table 6 Global Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
  • Table 7 Global Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 8 Global Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 9 Global Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 10 Global Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 11 Global Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 12 Global Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
  • Table 13 Global Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 14 North America Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
  • Table 15 North America Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
  • Table 16 North America Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
  • Table 17 North America Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
  • Table 18 North America Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
  • Table 19 North America Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
  • Table 20 North America Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 21 North America Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 22 North America Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 23 North America Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 24 North America Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 25 North America Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
  • Table 26 North America Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 27 Europe Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
  • Table 28 Europe Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
  • Table 29 Europe Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
  • Table 30 Europe Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
  • Table 31 Europe Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
  • Table 32 Europe Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
  • Table 33 Europe Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 34 Europe Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 35 Europe Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 36 Europe Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 37 Europe Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 38 Europe Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
  • Table 39 Europe Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 40 Asia Pacific Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
  • Table 41 Asia Pacific Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
  • Table 42 Asia Pacific Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
  • Table 43 Asia Pacific Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
  • Table 44 Asia Pacific Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
  • Table 45 Asia Pacific Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
  • Table 46 Asia Pacific Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 47 Asia Pacific Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 48 Asia Pacific Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 49 Asia Pacific Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 50 Asia Pacific Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 51 Asia Pacific Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
  • Table 52 Asia Pacific Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 53 South America Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
  • Table 54 South America Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
  • Table 55 South America Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
  • Table 56 South America Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
  • Table 57 South America Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
  • Table 58 South America Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
  • Table 59 South America Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 60 South America Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 61 South America Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 62 South America Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 63 South America Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 64 South America Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
  • Table 65 South America Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 66 Middle East & Africa Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
  • Table 67 Middle East & Africa Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
  • Table 68 Middle East & Africa Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
  • Table 69 Middle East & Africa Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
  • Table 70 Middle East & Africa Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
  • Table 71 Middle East & Africa Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
  • Table 72 Middle East & Africa Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 73 Middle East & Africa Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 74 Middle East & Africa Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 75 Middle East & Africa Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 76 Middle East & Africa Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 77 Middle East & Africa Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
  • Table 78 Middle East & Africa Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)